LTRN (Lantern Pharma) EPS (Diluted) : $-1.78 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma EPS (Diluted)?

Lantern Pharma's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.42. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.78.

Lantern Pharma's EPS (Basic) for the three months ended in Sep. 2024 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.78.

Lantern Pharma's EPS without NRI for the three months ended in Sep. 2024 was $-0.42. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.78.

During the past 3 years, the average EPS without NRIGrowth Rate was -2.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Lantern Pharma's highest 3-Year average EPS without NRI Growth Rate was -2.40% per year. The lowest was -59.60% per year. And the median was -49.60% per year.

Lantern Pharma EPS (Diluted) Historical Data

The historical data trend for Lantern Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma EPS (Diluted) Chart

Lantern Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-0.39

-1.37

-1.13

-1.31

-1.47

Lantern Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Diluted)	Get a 7-Day Free Trial															-0.29	-0.39	-0.51	-0.46	-0.42

Competitive Comparison of Lantern Pharma's EPS (Diluted)

For the Biotechnology subindustry, Lantern Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantern Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's PE Ratio falls into.

Lantern Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Lantern Pharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-15.962	-	0)	/	10.842
	=	-1.47

Lantern Pharma's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-4.506	-	0)	/	10.763
	=	-0.42

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.78

Lantern Pharma (NAS:LTRN) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lantern Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantern Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201

Website

https://www.lanternpharma.com

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Executives

Leslie W. Kreis	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l.	10 percent owner	40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini	director	1223 FOXGLOVE LANE, WEST CHESTER PA 19380